- Home
- UTF vs SUPN Comparison
UTF vs SUPN Comparison
Compare UTF & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTF
- SUPN
- Stock Information
- Founded
- UTF 2004
- SUPN 2005
- Country
- UTF United States
- SUPN United States
- Employees
- UTF N/A
- SUPN N/A
- Industry
- UTF Finance Companies
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- UTF Finance
- SUPN Health Care
- Exchange
- UTF Nasdaq
- SUPN Nasdaq
- Market Cap
- UTF 2.5B
- SUPN 2.6B
- IPO Year
- UTF N/A
- SUPN 2012
- Fundamental
- Price
- UTF $25.61
- SUPN $45.46
- Analyst Decision
- UTF
- SUPN Buy
- Analyst Count
- UTF 0
- SUPN 2
- Target Price
- UTF N/A
- SUPN $43.00
- AVG Volume (30 Days)
- UTF 171.7K
- SUPN 638.4K
- Earning Date
- UTF 01-01-0001
- SUPN 11-03-2025
- Dividend Yield
- UTF 7.19%
- SUPN N/A
- EPS Growth
- UTF N/A
- SUPN 1411.53
- EPS
- UTF 2.84
- SUPN 1.14
- Revenue
- UTF $138,636,669.00
- SUPN $665,125,000.00
- Revenue This Year
- UTF N/A
- SUPN $4.84
- Revenue Next Year
- UTF N/A
- SUPN $17.69
- P/E Ratio
- UTF $9.16
- SUPN $40.79
- Revenue Growth
- UTF 19.80
- SUPN 5.55
- 52 Week Low
- UTF $22.05
- SUPN $29.16
- 52 Week High
- UTF $26.53
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- UTF 26.55
- SUPN 64.24
- Support Level
- UTF $25.84
- SUPN $45.26
- Resistance Level
- UTF $26.17
- SUPN $46.72
- Average True Range (ATR)
- UTF 0.26
- SUPN 1.04
- MACD
- UTF -0.10
- SUPN -0.24
- Stochastic Oscillator
- UTF 5.56
- SUPN 55.96
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.